Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells

Biomedicine and Pharmacotherapy

Volumn 61, Issue 6, 2007, Pages 338-346

  Naruse, T ^a   Nishida, Y ^a   Ishiguro, N ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclooxygenase 2; Meloxicam; Osteosarcoma

Indexed keywords

3 (4,5' DIMETHYLTHIAZOL 2 YL) 2,5' DIPHENYLTETRAZOLIUM BROMIDE; 4 HYDROPEROXYIFOSFAMIDE; CISPLATIN; CYCLOOXYGENASE 2; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DOXORUBICIN; MELOXICAM; PROTEIN BAX; PROTEIN BCL 2; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; HUMANS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZINES; THIAZOLES;

EID: 34547515956     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.02.011     Document Type: Article

References (45)

1. Eberhart C.E., Coffy R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of Cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 4 (1994) 1183-1188
2. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., and Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. The Prostate 42 (2000) 73-78
3. Hwang D., Scollard D., Byrne J., and Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90 6 (1998) 455-460
4. Liu X.H., Yao S., Kirschenbaum A., and Levin A.C. NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res 58 (1998) 4245-4249
5. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R.J., Morrow J., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99 (1997) 2254-2259
6. Yao M., Kargman S., Lam E.C., Kelly C.R., Zheng Y., Luk P., et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63 (2003) 586-592
7. Dickens D.S., Kozielski R., Leavey P.J., Timmons C., and Cripe T.P. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 25 (2003) 282-285
8. Naruse T., Nishida Y., Hosono K., and Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27 3 (2006) 584-592
9. Moalic S., Liagre B., Le Bail J., and Beneytout J.L. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 18 (2001) 533-540
10. Goldman A.P., Williams C.S., Sheng H., Lamps L.W., Williams V.P., Pairet M., et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19 (1998) 2195-2199
11. Tsubouchi Y., Mukai S., Kawahito Y., Yamada R., Kohno M., Inoue K., et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20 (2000) 2867-2872
12. Link M.P., Goorin A.M., Miser A.W., Green A.A., Pratt C.B., Belasco J.B., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 19 (1986) 1600-1606
13. Awara W.M., El-Sisi A.E., El-Sayad M.E., and Goda A.E. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?. Pharmacol Res 50 (2004) 487-498
14. Mizutani Y., Nakanishi H., Li Y.N., Sato N., Kawauchi A., and Miki T. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. Urology 172 (2004) 1474-1479
15. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn Jr. P.A., and Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59 (1999) 6178-6184
16. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50 (2000) 604-610
17. Steel G.G., and Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Oncol Biol Phys Radiat 5 (1979) 85-93
18. Haynes A., Shaik M.S., Chatterjee A., and Singh M. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res 20 9 (2003) 1485-1495
19. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6 (2000) 2006-2011
20. Lin J., Hsiao P.W., Chiu T.H., and Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70 (2005) 658-667
21. Sugiura T., Saikawa Y., Kubota T., Suganuma K., Otani Y., Watanabe M., et al. Combination chemotherapy with JTE-522, a novel selective Cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 17 (2003) 229-234
22. Ogino M., and Minoura S. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int J Clin Oncol 6 (2001) 84-89
23. Saikawa Y., Sugiura T., Toriumi F., Kubota T., Suganuma K., Isshiki S., et al. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res 24 (2004) 2723-2728
24. Duffy C.P., Elliott C.J., O'Connor R.A., Heenan M.M., Coyle S., Cleary I.M., et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34 8 (1998) 1250-1259
25. Kang H.K., Lee E., Pyo H., and Lim S.J. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 4 9 (2005) 1358-1363
26. Zatelli M.C., Luchin A., Piccin D., Tagliati F., Bottoni A., Vignali C., et al. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90 10 (2005) 5754-5760
27. Aggarwal S., and Gupta S. A possible role for multidrug resistance-associated protein in the secretion of basic fibroblast growth factor by osteogenic sarcoma cell line (MG-63). Int J Oncol 13 6 (1998) 1331-1334
28. Mauz-Korholz C., Dietzsch S., Banning U., Trobs R.B., and Korholz D. Heat- and 4-hydroperoxy-ifosfamide-induced apoptosis in B cell precursor leukaemias. Int J Hyperthermia 19 4 (2003) 444-460
29. Schwartz P.S., and Waxman D.J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 60 (2001) 1268-1279
30. Chu G. Cellular responses to cisplatin. J Biol Chem 269 2 (1994) 787-790
31. 2 phase of the cell cycle. Mol Cell Biol 21 15 (2001) 4929-4937
32. Cho H.J., Kim J.K., Kim K.D., Yoon H.K., Cho M.Y., Park Y.P., et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237 1 (2005) 56-66
33. Skaladanowski A., and Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 46 3 (1993) 375-382
34. Smith P.J., Rackstraw C., and Cotter F. DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells. Ann Hematol 69 (1994) S7-S11
35. Jurisicova A., Lee H.J., D'Estaing S.G., Tilly J., and Perez G.I. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ 13 9 (2006) 1466-1474
36. Friesen C., Herr I., Krammer P.H., and Debatin K.-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2 (1996) 574-577
37. Maier T.J., Schilling K., Schmidt R., Geisslinger G., and Grosch S. Cyclooxygenase-2 (COX-2) -dependent and -independent anticarcinogenic effects of rofecoxib in human colon carcinoma cells. Biochem Pharmacol 67 (2004) 1469-1478
38. 2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 9 (2003) 1302-1306
39. Subbegowda R., and Frommel T.O. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res 58 (1998) 2772-2776
40. Bonetti A., Zaninelli M., Leone R., Cetto G.L., Pelosi G., Biolo S., et al. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4 (1998) 2331-2336
41. Ogston K.N., Miller I.D., Schofield A.C., Spyrantis A., Pavlidou E., Sarkar T.K., et al. Can patient's likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?. Breast Cancer Res Treat 86 (2004) 181-189
42. Wagner A.J., Small M.B., and Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol 13 4 (1993) 2432-2440
43. Wang Y., Szekely L., Okan I., Klein G., and Wiman K.G. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8 12 (1993) 3427-3431
44. Sharma H., Sen S., and Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4 9 (2005) 949-955
45. Xu Z., Choudhary S., Voznesensky O., Mehrotra M., Woodard M., Hansen M., et al. Overexpression of Cox-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res 66 13 (2006) 6657-6664